Morgan Stanley

Morgan Stanley has been fined €20m by the Autorité des Marchés Financiers (AMF) for manipulation of French and Belgian government bond prices. The bank intends to appeal the fine.

Another packaging company is hunting for better financing terms in the issuer-friendly European high yield bond market. Berry Global follows companies such as Crown, Ball, Smurfit Kappa, Owen-Illinois and Ardagh with an ambitious refinancing that could be priced as early as Thursday — the day of the UK general election.

The Netherlands’ Prosus has raised its takeover offer for food delivery firm Just Eat to around £5.1bn. It has brought in a host of banks to finance the bridge facility, but the boss of opposing bidder Takeaway.com called Prosus' bid “derisory”.

A banker specialising in ratings advisory has left Morgan Stanley after spending more than six and a half years with the bank.

JS Global Lifestyle Co, a Hong Kong-based small appliance manufacturer, has started taking orders for its second attempt at a listing, launching bookbuilding on Monday at a fixed price.

India's REC, formerly known as Rural Electrification Corp, raised $500m from a five year bond on Thursday.

Akesobio, a Chinese biopharmaceuticals company, filed a draft prospectus for an IPO with Hong Kong’s stock exchange on Tuesday.

OneConnect Financial Technology, a unit of Chinese conglomerate Ping An Group, hit the road on Tuesday to meet investors for its New York Stock Exchange IPO.

Power company Electricité de France issued its third bond in quick succession on Monday, and investors piled into the book, seemingly little fazed by its heavy recent issuance.

Thai Beverage is planning to spin off and list its brewery business in a deal that could raise up to $2.5bn, according to a source familiar with the matter.

Oil and Natural Gas Corp (ONGC), the largest crude oil and natural gas company in India, tussled with bond investors during marketing for its latest dollar deal this week. Investors pushed back against ONGC’s demanding terms and forced a last-minute flip-flop over a change of control clause. Morgan Davis reports.

Alphamab Oncology, a Chinese biopharmaceutical firm, has launched a roadshow for an up to HK$1.83bn ($233.8m) listing, according to a source close to the deal.